COMPASS Pathways plc to announce second quarter 2022 financial results on...

PT341 – Monnica Williams, Ph.D. – Racism, Trauma, Research, and Psychedelics

Ecstasy for the 21st Century: Designer Drugs to Improve MDMA Therapy

HAVN Life Announces Financing Commitment of CAD$9,000,000 through the issuance of...

Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of...

PT340 – Joost Breeksema – The Interdisciplinary Conference on Psychedelic Research...

The Doors of Expression: LSD Alters Epigenetics and Protein Induction

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting...

Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of...

Load more